Category - Markets

Markets

HCW ups Bionomics to buy; PT to 30 cents from 3 cents

H.C. Wainwright upgraded Bionomics (ASX:BNO) to “buy” from “neutral” and raised its price target to 30c (Australian) from three cents after the company announced results of a pharmacokinetics (PK) study of the tablet...

September 26, 2019

Markets

BTIG starts NeuBase Therapeutics at buy; PT $15

BTIG initiated coverage of NeuBase Therapeutics (NASDAQ:NBSE) with a “buy” rating and $15 price target. The stock closed at $6.55 on Sept. 23. NeuBase has developed a modular antisense peptide nucleic acid (PNA)...

September 24, 2019

Markets

AGP starts coverage of 4 cannabis companies at buy

Alliance Global Partners launched coverage of four cannabis companies – Acreage Holdings (CSE:ACRG; OTCQX:ACRGF), GrowGeneration (OTCQX:GRWG), Village Farms International (TSX:VFF) and Green Thumb Industries...

September 19, 2019

Markets

WB starts Axsome Therapeutics at OP; fair value estimate $48

William Blair initiated coverage of Axsome Therapeutics (NASDAQ:AXSM) with an “outperform” rating and a fair value estimate of $48. The stock closed at $28.21 on Sept. 17. Axsome Therapeutics is focused on developing...

September 18, 2019

Markets

WB starts Minerva Neurosciences at OP; fair value estimate $26

William Blair launched coverage of Minerva Neurosciences (NASDAQ:NERV) with an “outperform” rating and fair value estimate of $26. The stock closed at $8.11 on Sept. 17. Minerva is developing therapies for mood...

September 18, 2019

Markets

SVB Leerink starts Axonics Modulation at OP; PT $45

SVB Leerink initiated coverage of Axonics Modulation Technologies (NASDAQ:AXNX) with an “outperform” rating and $45 price target. The stock closed at $30.27 on Sept. 16. “To us, Axonics represents a hyper-growth story...

September 17, 2019

Markets

TBIG starts Cellular Biomedicine at buy; PT $19

TBIG launched coverage of Cellular Biomedicine Group (NASDAQ:CBMG) with a “buy” rating and $19 price target. The stock closed at $14.84 on Sept. 16. Cellular has been developing its cGMP grade cell therapy manufacturing...

September 17, 2019

Markets

HCW ups Pluristem PT to $15.50 from $3.50 post reverse split

H.C. Wainwright raised its price target for Pluristem Therapeutics (NASDAQ:PSTI) to $15.50 from $3.50, reflecting a 10-for-1 reverse stock split and promising early results from a Phase 1 study. The stock closed at $4...

September 17, 2019

Markets

Dawson James starts BioCardia at buy; PT $24

Dawson James Securities launched coverage of BioCardia (NASDAQ:BCDA) with a “buy” rating and $24 price target. The stock closed at $4.84 on Sept. 16. BioCardia is a developing two different cell therapy systems to...

September 17, 2019

Markets

Roth starts Cellectar Biosciences at buy; PT $11

Roth Capital Partners launched coverage of Cellectar Biosciences (NASDAQ:CLRB) with a “buy” rating and $11 price target. The stock closed at $2.29 on Sept. 12. Cellectar is developing CLR 131, a targeted...

September 13, 2019

Category - Markets

Subscribe